177-Lu TE 1132
Alternative Names: 177Lu-TE-1132; TE-1132Latest Information Update: 18 Jan 2023
Price :
$50 *
At a glance
- Originator Immunwork
- Class Antineoplastics; Drug conjugates; Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action CA-19-9 antigen inhibitors; Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 10 Jan 2023 177-Lu TE 1132 is available for licensing as of 05 Jan 2023. https://www.immunwork.com/eforms.php?lang=en&tb=1
- 05 Jan 2023 Preclinical trials in Cancer in Taiwan (Parenteral) before January 2023 (Immunwork pipeline, January 2023)
- 05 Jan 2023 Pharmacodynamics data from preclinical studies in Cancer released by Immunwork (Immunwork pipeline, January 2023)